Foresee Pharma Signs Global License Deal for MMP-12 Inhibitors
Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) today announced, following approval at its 2025 Extraordinary General Shareholders’ Meeting, that Foresee Pharmaceuticals USA Inc., the Company’s fully-owned US...